CellBion Co., Ltd. (KOSDAQ:308430)
South Korea flag South Korea · Delayed Price · Currency is KRW
27,350
-550 (-1.97%)
At close: Aug 4, 2025, 3:30 PM KST

CellBion Company Description

CellBion Co., Ltd. engages in the research and development of radiopharmaceutical products.

Its clinical stage pipeline includes 177Lu-PSMA-DGUL, indicated for prostate cancer radiotherapy, currently under Phase 2 clinical stage; 225Ac-Antibody, indicated for multiple cancer types, currently under pre-clinical stage; 225Ac-DGUL, indicated for prostate cancer radiotherapy, currently under pre-clinical stage; 68Ga-Nota-MSA, indicated for cardiovascular disease diagnosis, currently under Phase 2 clinical stage; 99mTc-MSA-ICG, indicated for lymphoscintigraphy SLN mapping, currently under Phase 1 clinical stage; and 68Ga-NGUL, indicated for prostate cancer diagnosis, currently under Phase 2 clinical stage.

It is also involved in the development of preclinical stage pipeline comprising 68 Ga-FAP, indicated for solid tumors diagnosis; 225 Ac-FAP, indicated for solid tumors radiotherapy; and peptide-based radioligand therapy and antibody-radionuclide conjugates for undisclosed indications.

The company was founded in 2010 and is headquartered in Seoul, South Korea.

CellBion Co., Ltd.
CountrySouth Korea
Founded2010
IndustryPharmaceutical Preparations
CEOKweon Kim

Contact Details

Address:
103, Daehak-ro
Seoul, 03080
South Korea
Phone82 2 743 3311
Websitecellbion.co.kr

Stock Details

Ticker Symbol308430
ExchangeKOSDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyKRW
SIC Code2834

Key Executives

NamePosition
Kweon KimChief Executive Officer